AI주식인사이트AI Stock Insight
C

지노믹트리

228760KOSDAQ자연과학 및 공학 연구개발업

53.0 / 100

Reference Date: 2026-04-13

Financial Score24.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 16.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

GenomicTree is a South Korean company specializing in early cancer detection using biomarker-based molecular diagnostics, with its flagship product 'EarlyTect-Colon Cancer' approved in 2018. The test uses stool DNA and offers high sensitivity and rapid results, competing with traditional colonoscopies. The company is expanding globally through subsidiaries in the U.S. and a joint venture in China, though 2024 revenue declined due to the end of its coronavirus diagnostic business.

Number of Employees

76people

Average Salary

51.8M KRW

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 120.074.0Point
PBR
3.66Industry Average 3.824.0Point

In line with industry avg

ROE
-7.62Industry Average -32.113.5Point

Well below industry avg

Debt Ratio
0.87Industry Average 7.528.0Point

Half of industry avg (excellent)

Trend 2023~20255.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.1% (2-year basis)

Operating Profit Growth Rate
2.5 / 3

Avg ▲18.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -7.9% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (25%)

Current 16,960Won52-week high 32,00052-week low 11,850
1-month return0.0Point

1m -16.25% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral정기주주총회결과2026-03-26
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
  • Neutral사업보고서 (2025.12)2026-03-18
  • Neutral감사보고서제출2026-03-16